{"id":"W4245145323","doi":"10.1200/jco.2014.32.15_suppl.tps4150","title":"Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cabozantinib; Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Oncology; Placebo; Tolerability; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Randomized controlled trial; Phases of clinical research; Cancer; Adverse effect; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002544229,0.002238015,0.003901973,0.0006606801,0.000709989,0.001108926,0.001218648,0.002408705,0.01042442],"category_scores_gemma":[0.00234159,0.001002966,0.001774677,0.0005449135,0.001582722,0.001360744,0.0004280595,0.003228799,0.001838636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008860218,"about_ca_system_score_gemma":0.001800656,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001181828,"about_ca_topic_score_gemma":0.002919587,"domain_scores_codex":[0.9991164,0.000465188,0.00004610304,0.0001695924,0.00006989977,0.0001328398],"domain_scores_gemma":[0.9986944,0.0003624104,0.0003358762,0.00009711336,0.0001178657,0.0003924758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.983475,0.007942433,0.0002645935,0.0003500528,0.0003923979,0.00002963596,0.00003204482,0.0001275894,0.002001433,0.00005164953,0.0006732509,0.004659872],"study_design_scores_gemma":[0.960099,0.03836716,0.0007190956,0.00001035237,0.0001091371,0.0000164251,0.00001052893,0.0002004993,0.0001409106,0.00006145124,0.0002583254,0.000007061769],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.960336,0.005332653,0.002284276,0.001343992,0.001453866,0.02180813,0.003463994,0.0006546399,0.003322398],"genre_scores_gemma":[0.957232,0.002578946,0.004053898,0.002570482,0.0007866022,0.02477951,0.002361151,0.00007843052,0.005558964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01042442,"threshold_uncertainty_score":0.03487313,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1816199510609935,"score_gpt":0.4133839541499895,"score_spread":0.2317640030889961,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}